A phase III trial of sunitinib has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, researchers report at the ESMO 2016 Congress in Copenhagen.
New eUpdate featuring updated treatment algorithms for Prostate Cancer
Anticancer drug discovery
Microbiota-epithelial cell crosstalk
Studying tumours early in development can reveal therapeutic targets that can boost the efficacy of treatments administered later in disease progression
Successful implementation of immunotherapy in breast cancer management requires the optimisation of current immunotherapeutic regimens and the identification of immunological biomarkers
It is approved in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
Researchers identify mutations expressed within melanoma that predict effective responses to a groundbreaking immunotherapy
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 Congress in Copenhagen.
New eUpdate featuring an updated treatment algorithm and recommendations for Chronic Lymphocytic Leukaemia
Therapeutic strategies to minimise or eliminate residual disease
Results from exploratory trial of evaluation of combination treatment
Gene expression pathways and putative somatic driver aberrations are consistent across metastases within an individual
Experimental paradigm could potentially improve preclinical evaluation of treatment modalities and enhance ability to predict clinical trial responses
ESMOChannel: S. Peters & G. Tortora present an overview of Signalling Pathways 2015 pmme #personalisedmedicine goo.gl/7VAAwK
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva,
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.
Strategies and challenging aspects in the treatment of haematological malignancies and solid tumours
Immune effects of imatinib
Biomarkers targetable by currently existing agents were also identified
Early-career oncologists, pathologists and basic science PhD students: apply now to join the Pre-IMPAKT 2016 training course
New website section dedicated to research funding opportunities created to promote and improve clinical cancer research in Europe
The phase II study results
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine (NEJM). The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.
ESMO President, R. Stahel announces his vision for the society. Focus on research: developing a better environment for clinical and translational research in Europe to find better treatments for cancer
Rigorous preoperative assessment advisable for older patients with mesothelioma prior to extended pleurectomy decortication
Download our A4 poster with all the IMPAKT 2016 deadlines and dates!
El cáncer de pulmón es el más frecuente del mundo, con más de 1.800.000 nuevos casos al año ow.ly/EoJpP
Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to